Clinical and laboratory characteristics of groups.*

RA: rheumatoid arthritis; FM: fibromyalgia; FIQ: fibromyalgia impact questionnaire; FIQ pain: “How much pain did you experience in the last seven days?”; RA: rheumatoid arthritis; DMARD: disease-modifying antirheumatic drugs; NSAID: non-steroidal anti-inflammatory drugs; mg: milligrams; HAQ: health assessment questionnaire; DAS28: disease activity score of 28 joints with 4 variables (tender joints count, swollen joint count, patient visual analog scale, erythrocyte sedimentation rate); SDAI: simplified disease activity index with 5 variables(tender joints count, swollen joint count, patient visual analog scale, physician visual analog scale, C-reactive protein); CDAI: clinical disease activity index with 4 variables (tender joints count, swollen joint count, patient visual analog scale, physician visual analog scale); GS-US7: gray-scale 7-joint ultrasound score; PD-US7: power Doppler 7-joint ultrasound score; US: ultrasound.*Values are median (25th, 75th percentiles) or percentage¶Two-tailed Wilcoxon’s or McNemar’s tests; P§Score (range)†Pain medications: tricyclic antidepressants, selective serotonin reuptake inhibitors, cyclobenzaprine, duloxetine, pregabalin or tramadolClinical and laboratory characteristics of groups.*